Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Knighthood For AstraZeneca’s Mene Pangalos

Data Breach Takes Shine Off UK Honours List

Executive Summary

Mene Pangalos is given a knighthood for services to UK science, alongside NHS England’s Simon Stevens and Quintiles founder Dennis Gillings.

You may also be interested in...



AZ’s Farxiga Gets FDA Priority Review For Heart Failure

AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.

AC Immune and J&J Advance Tau-Targeting Alzheimer’s Vaccine

AC Immune has seen two big disappointments in its Alzheimer’s pipeline this year, but its partner Johnson & Johnson has put its faith in a novel vaccine-like approach to targeting the disease.

Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat

Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC141400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel